ASMANEX HFA Rx
Generic Name and Formulations:
Mometasone furoate 100mcg, 200mcg; per actuation; metered-dose inhaler with dose counter.
Merck & Co., Inc.
Indications for ASMANEX HFA:
Maintenance treatment of asthma as prophylactic therapy.
Limitations Of use:
Not for relief of acute bronchospasm.
Previously on inhaled medium-dose corticosteroids: use 100mcg strength. Previously on inhaled high-dose or oral corticosteroids (wean gradually): use 200mcg strength. For both: Two inhalations twice daily (AM & PM). Rinse mouth after use.
Primary treatment of status asthmaticus or acute asthma attacks.
Maintain regular regimen. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Re-evaluate immediately during rapidly deteriorating asthma; may need oral corticosteroid therapy. Immunosuppressed. Untreated infections (eg, fungal, bacterial, viral, parasitic), TB, ocular herpes simplex. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. Transferring from systemic steroids: taper gradually. If adrenal insufficiency exists following systemic corticosteroids, replacement with inhaled steroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Monitor for bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occurs, discontinue gradually). Glaucoma, increased intraocular pressure, and cataracts: consider eye evaluation if ocular symptoms develop or in long term use. Severe hepatic impairment. Labor & delivery. Pregnancy. Nursing mothers: not recommended.
Potentiated by ketoconazole or other strong CYP3A4 inhibitors (eg, ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin); use caution and monitor.
Nasopharyngitis, headache, sinusitis, bronchitis, influenza; hypersensitivity reactions, paradoxical bronchospasm; discontinue if occurs.
Inhaler—13g (120 inh)
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally